|
|
Volumn 12, Issue 1, 2005, Pages 45-49
|
|
Rethinking innovation in pharmaceutical R & D
|
|
Author keywords
Best in class products; First in class products; Organisational innovation; Pipeline challenges; R and D investments; Risk management; Scientific innovation
|
|
Indexed keywords
DRUG PRODUCTS;
INDUSTRY;
PRODUCTIVITY;
RISK ASSESSMENT;
RISK MANAGEMENT;
STRATEGIC PLANNING;
BEST-IN-CLASS PRODUCTS;
FIRTS-IN-CLASS PRODUCTS;
ORGANISATIONAL INNOVATION;
PIPELINE CHALLENGES;
R&D INVESTMENTS;
SCIENTIFIC INNOVATION;
RESEARCH AND DEVELOPMENT MANAGEMENT;
AMLODIPINE BESYLATE;
ATORVASTATIN;
DRUG;
ESOMEPRAZOLE;
FLUTICASONE PROPIONATE PLUS SALMETEROL;
LANSOPRAZOLE;
OLANZAPINE;
PAROXETINE;
RECOMBINANT ERYTHROPOIETIN;
SERTRALINE;
SIMVASTATIN;
ARTICLE;
COMMERCIAL PHENOMENA;
DRUG INDUSTRY;
DRUG RESEARCH;
HEALTH CARE DELIVERY;
PRODUCTIVITY;
RISK MANAGEMENT;
ACARI;
HARNESS;
|
|
EID: 29444433526
PISSN: 14628732
EISSN: None
Source Type: Journal
DOI: 10.1057/palgrave.jcb.3040147 Document Type: Article |
|
Times cited : (10)
|
|
References (1)
|
